Ironwood Pharmaceuticals, Inc. (IRWD)

Market Cap	125.56M
Revenue (ttm)	317.68M
Net Income (ttm)	-32.34M
Shares Out	161.82M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	2.46
Dividend	n/a
Ex-Dividend Date	n/a

Volume	864,748
Open	0.8200
Previous Close	0.8043
Day's Range	0.7635 - 0.8200
52-Week Range	0.5271 - 7.1050
Beta	0.30
Analysts	Buy
Price Target	4.94 (+536.68%)
Earnings Date	Aug 7, 2025

About IRWD

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: Feb 3, 2010
• Employees: 253
• Stock Exchange: NASDAQ
• Ticker Symbol: IRWD
• Website: https://ironwoodpharma.com

Analyst Summary

According to 5 analysts, the average rating for IRWD stock is "Buy." The 12-month stock price target is $4.94, which is an increase of 536.68% from the latest price.

Price Target

$4.94

(536.68% upside)

Analyst Consensus: Buy